Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) posted its quarterly earnings results on Wednesday. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. Get Enliven Therapeutics alerts:Wall Street Analyst Weigh InSeveral brokerages recently issued reports on ELVN. Enliven Therapeutics Company Profile(Get Free Report)Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Featured StoriesReceive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.